Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

Pharmacist Immunisation SSTP Revocation and Approval

I, Christine Maree Connors, Chief Health Officer:

(a) under section 254(5) of the Medicines, Poisons and Therapeutic Goods Act 2012, (the

Act), revoke the instrument titled "Immunisation Scheduled Substance Treatment

Protocol (SSTP) for Pharmacists Approval" dated 7 December 2023; and

(b) under section 254(1) of the Act, approve each Scheduled substance treatment protocol

specified in Schedule A;

(c) under section 254(3) of the Act, state that each Schedule substance treatment protocol

specified in Schedule A remains in effect for a period of 2 years on and from the date

of this instrument.

Dated

31/01/2025 EDOC2025/23882

Chief Health Officer

## Schedule A

Title	Publication Date	Author	
Immunisation Scheduled	29 January 2025	Medicines and Poisons,	
Substance Treatment		Northern Territory	
Protocol (SSTP) for		Government, Department of	
Pharmacists V2		Health	

## Immunisation Scheduled Substance Treatment Protocol (SSTP) for Pharmacists V2

Areas Applicable	NT Wide		
Health Professionals authorised by this SSTP	Pharmacists		
Scheduled	COVID 19 Vaccine		
Substance(s)	Diphtheria Vaccine		
	Haemophilus influenza type B (Hib) Vaccine		
	Hepatitis A Vaccine		
	Hepatitis B Vaccine		
	Human Papillomavirus Vaccine		
	Influenza Vaccine		
	Japanese Encephalitis Vaccine		
	Measles Vaccine		
	Meningococcal Vaccine		
	Mumps Vaccine		
	Pertussis (Whooping Cough) Vaccine		
	Pneumococcal Vaccine		
	Poliomyelitis Vaccine		
	Respiratory syncytial virus (RSV) Vaccine		
	Rotavirus Vaccine		
	Rubella Vaccine		
	Tetanus Vaccine		
	Varicella (Chickenpox) Vaccine		
	Zoster (Herpes Zoster) Vaccine		
Indication	Immunisation against vaccine preventable diseases in persons aged 5 years and older.		
	This includes:		
	1) Vaccination in line with funded programs delivered under the NT Immunisation Schedule or National Immunisation Program.		
	2) Privately funded primary course vaccination and booster doses for individuals recommended by the current version of the Australian Immunisation Handbook. This extends to individuals with specific medical conditions and those at an elevated risk of exposure to vaccine-preventable diseases due to occupational or lifestyle factors		



Contraindications and/or Exclusions	Note: a referral to a medical practitioner may be required for serological testing and result interpretation to determine suitability for vaccination where stated in the AIH  As per the current Australian Immunisation Handbook and; Pharmacists may only administer vaccines to patients aged 5 years and above and; Where the Australian Immunisation Handbook states vaccination is not recommended for specific cohorts, such as pregnant women or			
	immunocompromised patients, this protocol cannot be used in that group			
Dose and Route	Dose as per the current version Australian Immunisation Handbook			
Administration	Immunisation providers should screen people for eligibility before vaccination, obtain valid consent, and ensure that the correct equipment and procedures are in place before vaccination.			
	Management of Anaphylaxis			
	Administration of any vaccine from this protocol must occur where another person, who holds a current Basic Life Support Certificate or Provide First Aid Certificate, is immediately available to provide emergency assistance if required			
	Administration of any vaccine from this protocol must occur where there is a complete anaphylaxis Emergency Response Kit for the use in treatment and management of anaphylaxis in line with procedures from the current Australian Immunisation Handbook			
	<ul> <li>Emergency Response Kit must be checked regularly, maintained, be easily accessible and contain:</li> </ul>			
	o Adrenaline 1:1000 (minimum of 3 ampoules)			
	o 1mL syringes and 25mm needles for IM injection (minimum of 3 of each)			
	o Cotton wool swabs			
	<ul> <li>Pen and paper to record time of administration of adrenaline</li> </ul>			
	<ul> <li>Laminated copy of 'Recognition and treatment of anaphylaxis' and the 'Doses of intramuscular 1:1000 adrenaline for anaphylaxis' available from the <u>Table. Recognition and treatment of anaphylaxis   The Australian Immunisation Handbook (health.gov.au)</u></li> </ul>			
	Administration Premises Requirements			
	All Premises			
	All vaccines must be administered in a location, service and manner that allows the practitioner to manage anaphylaxis including emergency response kit outline above.			
	Pharmacy Premises			
	Vaccines administered on a pharmacy premises must also meet the requirements as outlined in the current PS5 Premises & Equipment Standard for Pharmacy Based Immunisations.			
	Non-Pharmacy Premises			

	Vaccines administered in a location other than a pharmacy premises must:				
	ensure privacy of the consumer				
	<ul> <li>ensure sufficient room to accommodate the consumer, carer and immuniser and allow sufficient space, surfaces and be able to respond to medical emergencies including sufficient space for the consumer to lie down if required</li> </ul>				
	have equipment to facilitate safe immunisation administration including				
	<ul> <li>Easy access to a sink with running water and hand soap for washing hands and/or ready access to hand sanitiser</li> </ul>				
	<ul> <li>Sharps disposal container and dedicated bin for medical waste</li> </ul>				
	<ul> <li>Equipment and storage facilities to meet the National Vaccine Storage Guidelines</li> </ul>				
	<ul> <li>Consumables for the delivery of a vaccine eg needles, hypoallergenic tape, cottonwool swabs and/or adhesive bandage strips</li> </ul>				
Dose Frequency	Dosing frequency, and intervals between vaccines, as per the current version NT Immunisation Schedule and Australian Immunisation Handbook				
Drug Interactions	As per interactions listed in the current Australian Immunisation Handbook and individual vaccine product information.				
Monitoring requirements	Post vaccination procedures should be followed as per the Australian Immunisation Handbook.				
	All patients must be monitored post vaccination for 15 minutes unless they withdraw consent to be monitored. Ensure withdrawn consent is documented in the person's clinical record.				
	Report any adverse event during or post vaccination to the NT Centre for Disease Control using the 'Adverse event following vaccination' form available online or in hard copy on the Recording and reports on immunisations   NT Health				
Health Professional	Pharmacists				
Accreditation Requirements	Be registered with the Pharmacy Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients				
	And:				
	Hold a current certificate of completion of either:				
	Prior to 1 January 2017:				
	<ul> <li>APPIMM806A - Manage the delivery and administration of injections and immunisations -Pharmaceutical Society of Australia; or</li> </ul>				
	<ul> <li>10455NAT - Course in conduct immunisation services within a community pharmacy environment - Pharmacy Guild of Australia;</li> </ul>				
	After 1 January 2017:				
	<ul> <li>a training program accredited as meeting the standards set by the Australian Pharmacy Council's 'Standards for the accreditation of programs to support Pharmacist Administration of vaccines'.</li> </ul>				

	<ul> <li>Maintain continuing professional development related to skills and competencies required for the delivery of medicines and COVID-19 vaccines including the use of multi-dose vials and management of anaphylaxis</li> <li>Hold a current Cardiopulmonary Resuscitation (CPR) certificate</li> </ul>				
Documentation (including necessary information to the patient)	Patient consent (written or verbal) for vaccination must be recorded. Records of consent are to be maintained by the clinical service.  The health professional must:  Complete all clinical documentation requirements as outlined by the Health Service				
	<ul> <li>Enter the patient details, vaccine brand name, dose, site of administration and batch number in the Australian Immunisation Register within 24 hours, and no later than 10 days, after administration. For many vaccine providers this involves entry into routine clinical information systems for automatic upload.</li> </ul>				
Related Documents	<ul> <li>Immunisation Program   NT Health</li> <li>The Australian Immunisation Handbook (health.gov.au)</li> <li>National vaccine storage guidelines - Strive for 5, 3rd edition (health.gov.au)</li> <li>ASCIA Guidelines - Acute Management of Anaphylaxis</li> <li>Pharmacy Premises Standard - PS5 - Premises and Equipment Standard for Pharmacy Based Immunisation Programs</li> </ul>				
Chief Health Officer	Signature	Name	Date		
	EDOC2025/23880	Dr Christine Connors Chief Health Officer	31/01/2025		
Period of effect	This SSTP remains in force until 31/01/2027 or revoked earlier.				

## References:

<sup>\*</sup> The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration